Dr. Loomba is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
9350 Campus Point Dr
La Jolla, CA 92037Phone+1 619-543-5415Fax+1 619-543-3183- Is this information wrong?
Summary
- Dr. Rohit Loomba is a gastroenterologist in La Jolla, CA and is affiliated with UC San Diego Health. He received his medical degree from Armed Forces Medical College Pune and has been in practice 23 years. He also speaks multiple languages, including Hindi, Punjabi, and Urdu. He specializes in hepatology & liver transplantation and is experienced in general gastroenterology, hepatology, hepatic cirrhosis, transplant hepatology, and biliary tract disease.
Education & Training
- University of California (San Diego) Medical CenterFellowship, Gastroenterology, 2007 - 2009
- Duke University School of MedicineMHS, Clinical Research, 2005 - 2007
- Clinical Center at the National Institutes of HealthFellowship, Transplant Hepatology, 2004 - 2007
- St Luke's HospitalResidency, Internal Medicine, 2000 - 2003
- ArMed Forces Medical College PuneClass of 1999
Certifications & Licensure
- CA State Medical License 2007 - 2024
- MD State Medical License 2004 - 2010
- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Clarivate™ Highly Cited Researcher Across All Fields in Science Globally Web of Science, 2020
- Inducted as an elected member American Society of Clinical Investigation, 2019
- Clarivate™ Highly Cited Researcher - 1 in a 1000 based upon global impact Web of Science, 2019
- Join now to see all
Clinical Trials
- Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2 Start of enrollment: 2009 Dec 02
- Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis Start of enrollment: 2010 Feb 01
- Alpha-1 Antitrypsin Deficiency Adult Liver Study Start of enrollment: 2013 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.Veeral Ajmera, Kaleb Tesfai, Erick Sandoval, Scarlett Lopez, Vanessa Cervantes, Egbert Madamba, Ricki Bettencourt, Pinelopi Manousou, Lisa Richards, Rohit Loomba, Loom...> ;Hepatology. 2024 May 1
- A prospective study on the prevalence of at-risk MASH in patients with type 2 diabetes mellitus in the United States.Nikita Mittal, Harris Siddiqi, Egbert Madamba, Lisa Richards, Ricki Bettencourt, Veeral Ajmera, Rohit Loomba> ;Alimentary Pharmacology & Therapeutics. 2024 Apr 8
- High concordance between nonalcoholic fatty liver disease and metabolic dysfunction associated steatotic liver disease in the TARGET-NASH real world cohort.A Sidney Barritt 4th, Feng Yu, Andrea R Mospan, Philip Newsome, Michael Roden, Heather L Morris, , Rohit Loomba, Brent A Neuschwander-Tetri> ;The American Journal of Gastroenterology. 2024 Apr 8
- Join now to see all
Journal Articles
- The Lancet Child & Adolescent HealthArun Sanyal, Stephen A Harrison, Edgar D Charles, Stephanie Noviello, Manal F Abdelmalek, Eric J Lawitz, Rohit Loomba, The Lancet
- Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic SteatohepatitisRohit Loomba, Ariel E Feldstein, The Journal of Immunology
- Author Correction: Inflammation-Induced IgA+ Cells Dismantle Anti-Liver Cancer ImmunityRohit Loomba, MD, Nature
- Join now to see all
Abstracts/Posters
- Treatment with selonsertib, an inhibitor of apoptosis signal regulating kinase 1, hepatic phospho-p38 expression and markers of hepatocellular apoptosis and necrosis i...Diehl A.M., French D, Xu R, Loomba R, Lawitz E, Freilich B, Shiffman M.L., Chalasani N, Hameed B, Caldwell S, Rinella M, Peach M, Huntzicker E, Turner S, Sullivan T, C..., EASL, 1/1/2017
- Improvement of hepatic fibrosis in patients with non-alcoholic steatohepatitis treated with selonsertib is associated with improvement of patient-reported outcomes (PROS)Younossi Z.M., Stepanova M, Goodman Z, Lawitz E, Charlton M, Loomba R, Hunt S., EASL, 1/1/2017
- Methylation signatures in blood show accelerated epigenetic aging in patients with non-alcoholic steatohepatitis compared to healthy controls.Loomba R, Gindin Y, Jiang Z, Lawitz E, Djedjos C.S., Caldwell S, Xu R, Gong D, Myers R.P., Subramanian G.M., Goodman Z, Charlton M, Afdhal N.H., A.M. Diehl A.M., EASL, 1/1/2017
- Join now to see all
Lectures
- Novel Imaging and Management of NASH1/1/2017
- Imaging assessment of NAFLDNorthwestern University, Chicago, IL - 1/1/2016
- Novel phenotyping and imaging advances in NAFLDLiver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, NIH) - 1/1/2016
- Join now to see all
Authored Content
- UCSD Presence at AASLD the Liver Meeting 2023October 2023
Press Mentions
- Coffee May Reduce Liver Disease Severity in People with Type 2 DiabetesJanuary 12th, 2023
- 89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in the Lancet Gastroenterology & HepatologyDecember 12th, 2022
- Study: First-Degree Relatives of Patients with NAFLD at Risk of Liver DiseaseNovember 1st, 2022
- Join now to see all
Professional Memberships
- American Association for the Study of Liver DiseasesMember
- Member
- Member
- The American Society of Clinical InvestigationMember
- American Association for the Advancement of ScienceMember
Other Languages
- Hindi, Punjabi, Urdu
Hospital Affiliations
- UC San Diego Medical Center - HillcrestSan Diego, California
External Links
- UCSD NAFLD Research Centerhttps://healthsciences.ucsd.edu/som/medicine/divisions/gastro/research/NAFLD/pages/default.aspx
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: